RET and non-small cell lung carcinoma: Another more-recent study also identified concurrent genetic alterations of EGFE with MEK, ALK, KRAS, ROS1, TP53, PIK3CA, and PTEN in NSCLC (Guo et al., 2020b), while Tang et al. (Tang et al., 2018) reported coexistent genetic alterations involving ALK, RET, ROS1, and MET in 15 cases of lung adenocarcinoma (Tang et al., 2018).